Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Valued at a market cap of $204.3 billion, Merck & Co., Inc. (MRK) is a global healthcare company with a diverse portfolio ...

Merck is scheduled to release its earnings report on Thursday, April 24, 2025. Historical data suggests that MRK stock often reacts negatively to such announcements. Over the past five years, the ...

Merck doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck KGaA (OTCMKTS:MKKGY – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Merck KGaA to post earnings of $0.47 per ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released ...

These slides, along with the earnings release, today's prepared remarks, and our SEC filings are all posted to the Investor Relations section of Merck's website.

Merck was up 10% YTD as of Friday, August 30 ’24, but had been up as much as 21% at various times through the 2nd quarter, but the Q2 ’24 earnings release put a big dent in Merck, dropping the ...

A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com.